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Performance of prostate cancer recurrence
nomograms by obesity status: a
retrospective analysis of a radical
prostatectomy cohort
Charnita Zeigler-Johnson1* , Aaron Hudson2, Karen Glanz3, Elaine Spangler3 and Knashawn H. Morales3
Abstract
Background: Obesity has been associated with aggressive prostate cancer and poor outcomes. It is important to
understand how prognostic tools for that guide prostate cancer treatment may be impacted by obesity. The goal
of this study was to evaluate the predicting abilities of two prostate cancer (PCa) nomograms by obesity status.
Methods: We examined 1576 radical prostatectomy patients categorized into standard body mass index (BMI)
groups. Patients were categorized into low, medium, and high risk groups for the Kattan and CaPSURE/CPDR scores,
which are based on PSA value, Gleason score, tumor stage, and other patient data. Time to PCa recurrence was
modeled as a function of obesity, risk group, and interactions.
Results: As expected for the Kattan score, estimated hazard ratios (95% CI) indicated higher risk of recurrence for
medium (HR = 2.99, 95% CI = 2.29, 3.88) and high (HR = 8.84, 95% CI = 5.91, 13.2) risk groups compared to low risk
group. The associations were not statistically different across BMI groups. Results were consistent for the CaPSURE/
CPDR score. However, the difference in risk of recurrence in the high risk versus low risk groups was larger for
normal weight patients than the same estimate in the obese patients.
Conclusions: We observed no statistically significant difference in the association between PCa recurrence and
prediction scores across BMI groups. However, our study indicates that there may be a stronger association
between high risk status and PCa recurrence among normal weight patients compared to obese patients. This
suggests that high risk status based on PCa nomogram scores may be most predictive among normal weight
patients. Additional research in this area is needed.
Keywords: Biochemical recurrence, CaPSURE/CPDR score, Kattan score, Obesity, Prostate Cancer
Background
Prostate cancer (PCa) is a major public health burden
with few confirmed risk factors [1]. Obesity, a common
and potentially modifiable risk factor, affects approxi-
mately 20% to 30% of individuals with PCa [2–4] and
appears to increase the risk of advanced PCa at diagnosis
and risk for treatment failure [4–12]. Obese men also
may be at increased risk for PCa-specific and/or overall
mortality [9, 10], however not all studies support this
relationship [3]. Therefore, it is important to understand
the impact of obesity on tools used to aid in prognosti-
cation and guidance of treatment decisions.
Clinicians determine which cancer patients should re-
ceive definitive treatment by relying on nomograms.
Nomograms are models that can predict PCa recurrence
up to 10 years after the time of treatment with relatively
high accuracy (71–79%) compared to other risk grouping
methods [13, 14]. The Kattan nomogram, one of the most
commonly used tools for predicting risk for PCa recurrence
[15], includes information about year of radical prostatec-
tomy, positive surgical margins, extracapsular extension,
seminal vesicle invasion, lymph node invasion, primary and
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secondary Gleason grades, and preoperative PSA [16]. The
CaPSURE/CPDR recurrence equation includes information
about patient race, sigmoid transformed PSA, pathology
stage (including organ confined vs. extracapsular disease),
and post-operative Gleason sum [17].
Despite the widespread use of the Kattan and CaP-
SURE/CPDR as prognostic tools, it remains unclear
how well they predict disease recurrence in obese pa-
tients of different PCa risk groups. We analyzed the
predicting abilities of the 2 nomograms for PCa re-
currence by obesity status. We hypothesized that the
predicting ability of both nomograms would differ by
body mass index (BMI) group depending on PCa risk
status.
Methods
This secondary data analysis was conducted using a sample
of 2088 radical prostatectomy patients from the Study of
Clinical Outcomes, Risk, and Ethnicity (SCORE) [18, 19]. In-
cident PCa cases were recruited at the University of Pennsyl-
vania Health System (UPHS, Philadelphia, PA). Patients were
excluded from this analysis based on the following criteria:
not African American or Caucasian (N= 39), missing all var-
iables used to calculate the risk score leaving no information
for the imputation model (N= 13), missing information
needed to calculate survival time (N= 213), missing informa-
tion required to calculate BMI (N= 259), did not have sur-
gery date recorded (N= 55), and status of cancer recurrence
unknown (N= 217). After patients were excluded from the
analysis, there was a final sample of 1576 patients. Informed
consent was obtained from all individual participants in-
cluded in the study under a protocol approved by the Institu-
tional Review Board at the University of Pennsylvania and
that conformed to provisions of the Declaration of Helsinki.
Obesity was defined using BMI categories. Patients with
a BMI greater than 30 kg/m2 were classified as obese, pa-
tients with a BMI between 25 kg/m2 and 30 kg/m2 were
classified as overweight. Eleven men met criteria for
underweight (BMI < 19.5 kg/m2), but due to the small
number, they were grouped with the normal weight cat-
egory. Prostate cancer recurrence was defined as two PSA
levels recorded above 0.2 ng/ml at any time after initial
radical prostatectomy treatment. A total of 550 (35%) pa-
tients were missing information necessary for score calcu-
lation, so multiple imputation methods were used to
prevent unnecessarily discarding data. Specifically, 476
were missing primary pathology Gleason grade, 511 were
missing secondary pathology Gleason grade, and less than
40 were missing pathology Gleason score, PSA, extracap-
sular extension, surgical margin, seminal vesicle invasion,
or lymph node involvement. Baseline and clinical charac-
teristics were compared between the group with complete
data and the group with missing data using T-test or
Chi-square test as appropriate. A multiple imputation
model was implemented within SAS v9.3 using a fully
conditional specification (FCS) method for arbitrary miss-
ing data patterns [20]. The process, implemented in two
phases, started with a fill-in phase where the values are
filled-in one variable at a time and serve as starting values
for the imputation phase. The imputation phase used the
discriminant function method for binary covariates and
regression method for continuous covariates. The multiple
imputation process, which produced 5 imputed datasets
after 20 burn-in samples per imputation, included all vari-
ables used to calculate the scores in addition to the clinical
Gleason score. Trace plots were evaluated to ensure there
were no systematic trends in the burn-in samples prior to
the imputation sample.
Patients were categorized into recurrence risk groups
using the Kattan nomogram and the CaPSURE/CPDR re-
currence equation. Each risk score was considered in separ-
ate analyses. Using the Kattan nomogram, patients with a
score between 50 and 100 were defined to be at a high risk
of recurrence, patients with a score between 10 and 50
were defined to be at a medium risk of recurrence, and pa-
tients with a score less than 10 were defined to be at a low
risk of recurrence. Using the CaPSURE/CPDR equation,
patients with a score greater than 16.7 were defined to be
at a high risk, patients with a score between 7.1 and 16.7
were defined to be at a medium risk, and patients with a
score less than 7.1 were defined to be at a low risk [17].
Relationships between BMI groups and patient charac-
teristics at time of diagnosis were assessed using Chi-
square tests or Fisher’s exact test and ANOVA or
Kruskal-Wallis test, depending on the distribution of the
variables. Age, PSA and years since surgery were collected
by medical record abstraction. Marital status, race,
education, smoking and exercise data were collected
by patient survey. All baseline characteristics were in-
cluded because they have been associated with obesity
and/or prostate cancer outcomes in previous studies.
Bivariate relationships between time to PCa recur-
rence and patient characteristics were assessed using
Cox Proportional Hazards models. Variables that were
statistically significantly related to both obesity group
and PCa recurrence at the 0.10 level were included in
the final models.
Cox Proportional Hazards models were used to exam-
ine the association between time to recurrence and pre-
dicted risk recurrence group with potential effect
modification by BMI group. A separate model that con-
tained a main effect for obesity classification and the
interaction between risk group and obesity group was
developed for each risk score. Since the risk groups are
arbitrary, models using the continuous risk scores were
also fit. Descriptive analyses, multiple imputation, and
Cox models were implemented in SAS v 9.4 (SAS Institute
Inc., Cary, NC).
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The diagnostic accuracy in comparison to a gold stand-
ard, in this case the observed PCa recurrence, was quanti-
fied for each continuous risk score by obesity category
using a nonparametric estimimate of the area under the re-
ceiver operating characteristic curve (AUC) [21]. The
equality of the AUC across risk scores were compared
using a nonparametric test [22]. AUC analyses were imple-
mentd in Stata v 15 (StataCorp, College Station, TX).
Results
In comparing men with complete data to men is at least
one missing item, time since surgery was statistically dif-
ferent (p < 0.001) between those with complete data
(mean = 10.5 months, standard deviation = 5.1) and those
requiring imputation (mean = 15.3 months, sd = 5.5).
African American men had lower rates of missing data
compared to Caucasian men (21% vs 38%, Chi Square(df
= 1) = 33.83, p < 0.001). Current, former, and never
smokers also differed in rates of missing data (42.2%,
35.7%, and 29.1%, respectively; Chi Square(df = 2) = 11.83,
p = 0.003). The analysis sample after imputation included
a total of 1576 patients (383 obese, 820 overweight, and
373 normal weight).
Baseline characteristics and a summary of their relation-
ship with PCa recurrence and obesity groups appear in
Table 1. The follow-up time at which 25% of the men
experienced prostate cancer recurrence was 47 months for
obese patients, 70 months for overweight patients, and
121 months for normal weight men. In bivariate analyses, an
increase risk of PCa recurrence was associated with increas-
ing age and Arican American compared to Caucasian race.
Obesity status was associated with age, years since surgery,
PSA mass, exercise, smoking status, and race. The groups
differed in pathology with a higher proportion of obese men
having extracapsular extension, seminal vesicle invasion,
lymph node involvement, higher pathological Gleason score,
positive surgical margins, and adjuvant therapy compared to
the same in normal weight men (Table 2). Age and race, as-
sociated with both obesity group and PCa recurrence, were
included in adjusted models for the Kattan risk score. The
models for CaPSURE/CPDR included age and factors from
the Kattan risk score that are not included CaPSURE/CPDR
score (Table 2: seminal vesicle invasion, lymph node involve-
ment, adjuvant radiotherapy, and time since surgery).
Using the Kattan score, 61 patients (19 obese, 29 over-
weight, and 13 normal weight) were placed into the high
risk group, 333 patients (98 obese, 165 overweight, and
70 normal weight) into the medium risk group, and
1182 (266 obese, 626 overweight, and 290 normal
weight) into the low risk group. The CaPSURE/CPDR
score placed 75 patients (29 obese, 32 overweight, and
14 normal weight) into the high risk group, 473 (143
Table 1 Baseline characteristics and the association with obesity status and time to PCa recurrence
Patient Characteristic Obese (n = 383) Overweight (n = 820) Normal Weight (n = 373) F or Chi-Square
p-value
Hazard Ratio (95% CI)
Age in Years (Mean, SD) 58.6, 6.4 59.6, 6.8 60.0, 7.2 .014 1.009 (0.991,1.027)
Years Since Surgery (Mean, SD) 11.4, 5.8 12.2, 5.6 12.8, 5.9 .004 0.988 (0.965,1.011)
PSA mass μg (mean, SD) 89.8, 95.6 65.5, 65.8 50.0, 56.9 < 0.001 1.004 (1.004, 1.005)
Exercised, N (%) .009
More than once per week 144 (56.0) 344 (64.4) 157 (69.2) 1.084 (0.770,1.527)
Once per week or less 113 (44.0) 190 (35.6) 70 (30.8) Ref
Marital status, N (%) .161
Married 269 (79.1) 623 (83.6) 276 (83.6) 0.964 (0.692,1.342)
Unmarried 71 (20.9) 122 (16.4) 54 (16.4) Ref
Race, N (%) < 0.001
African American 103 (26.9) 160 (19.5) 59 (15.8) 1.564 (1.210,2.021)
Other 280 (73.1) 660 (80.5) 314 (84.2) Ref
Smoking status, N (%) .087
Current 31 (8.8) 56 (7.4) 41 (12.0) 1.440 (0.926, 2.240)
Former 161 (45.9) 334 (43.9) 135 (39.6) 1.244 (0.962,1.608)
Never 159 (45.3) 371 (48.8) 165 (48.4) Ref
Education, N (%) .165
College or higher 213 (61.9) 510 (66.1) 239 (68.7) 0.845 (0.657,1.086)
Less than college 131 (38.1) 262 (33.9) 109 (31.3) Ref
Summary statistics are provided prior to multiple imputation. Column percentages exclude missing data: PSA mass (n = 185), exercise (558), marital status (161),
smoking status (123), education (112)
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obese, 238 overweight, and 92 normal weight) into the
medium risk group, and 1028 (211 obese, 550 over-
weight, and 267 normal weight) in the low risk group.
Hazard ratios (95% CI) indicated the relative risk of PCa
recurrence for medium or high risk groups within each
obesity group (Table 3). In both models, the interaction
between risk group and obesity status was not statistically
significant (Kattan p = 0.752, CaPSURE p = 0.147). In
examining the Kattan score model within each obesity
group, we found that, as expected, patients with medium
and high risk scores had a higher risk of PCa recurrence
compared to low risk patients. Similar results were ob-
served in the CaPSURE/CPDR score model, with the ex-
ception that in the obese group, patients with high risk
scores were not statistically different from those with low
risk scores. Examining the high CaPSURE/CPDR column
of Table 3, the difference in risk of recurrence in the high
risk versus low risk groups is larger for normal weight pa-
tients than the same estimate in the obese patients.
Hazard ratio estimates and confidence intervals from the
observed data without imputation were similar to those
presented in Table 3, with the exception that high risk
scores were statistically different from those with low risk
scores for obese men (data not shown).
Kaplan-Meier survival curves were used to compare the
recurrence rates of patients by risk group and obesity
group using the CaPSURE/CPDR model (Fig. 1). Consist-
ent with results from Table 3, recurrence was more likely
to occur in the medium and high risk groups compared to
the low risk group (p < 0.001). However, within each PCa
risk group, lower recurrence rates were observed for nor-
mal weight compared to obese men. Using AUC analysis,
we also observed that the diagnostic accuracy for each risk
score was comparable. The area under the curve is 0.75
(95% CI: 0.72, 0.79) for the Kattan score and 0.74 (0.70,
0.77) for the CaPSURE score. (Fig. 2) However, there was
a suggestion of higher accuracy for the Kattan score in the
normal weight group compared to the overweight and
Table 2 Clinical characteristics used in the calculation of the risk score and the association with obesity status
Clinical Characteristics Factor in risk score calculation Obese
(n = 383)
Overweight
(n = 820)
Normal Weight
(n = 373)
F or Chi-Square
p-ValueKattan CaPSURE/CPDR
Pre-surgery PSA ng/mL,
mean, SD
X X 6.3, 6.2 6.1, 5.7 6.1, 6.5 0.861
Pathological staging
Extracapsular Extension,
N (%)
X X 125 (32.6) 204 (24.9) 87 (23.3) 0.005
Seminal Vesicle Invasion,
N (%)
X 37 (9.7) 43 (5.2) 29 (7.8) 0.016
Lymph Node, N (%) X 6 (1.6) 6 (0.7) 0 (0.0) 0.045
Pathological Gleason
Score
X 6.7, 0.8 6.5, 0.8 6.5, 0.9 0.001
Pathological Gleason
Grade1
≥ 4, N (%)
X 57 (14.9) 87 (10.6) 34 (9.1) 0.045
Pathological Gleason
Grade 2
≥ 4, N (%)
X 145 (37.9) 252 (30.7) 101 (27.1) 0.019
Surgery Year, range X 1990–2014 1989–2015 1987–2014
Surgical Margin, N (%) X 87 (22.7) 154 (18.8) 54 (14.5) 0.016
Adjuvant Radiotherapy, N (%) X 24 (6.3) 34 (4.2) 10 (2.7) 0.050
African American, N (%) X 103 (26.9) 160 (19.5) 59 (15.8) .001
Summary statistics are provided prior to multiple imputation. Missing data is as follows: pre-surgery psa [17], pathological gleason score [3], SVI [18], lymph node
[17], extracapsular extension [36], surgical margin [12], pgrade1 (476), pgrade2 (511). Complete data was available for surgery year and adjuvant radiotherapy
Table 3 Hazard ratios (95% confidence interval) of PCa recurrence for medium and high risk groups compared to the low risk group
by obesity status
Obesity Status Medium Kattan High Kattan Kattan scorea Medium CaPSURE/CPDR High CaPSURE/CPDR CaPSURE/CPDR scorea
Normal Weight 4.11 (2.20, 7.67) 13.2 (5.77, 30.1) 1.36 (1.25, 1.48) 3.83 (2.06, 7.14) 6.21 (2.60, 14.9) 3.16 (1.87, 5.34)
Overweight 2.89 (2.02, 4.13) 8.66 (4.71, 15.9) 1.37 (1.27, 1.46) 2.58 (1.77, 3.77) 4.64 (2.55, 8.44) 2.64 (1.89, 3.69)
Obese 2.56 (1.58, 4.15) 7.09 (3.54, 14.2) 1.32 (1.21, 1.44) 2.19 (1.26, 3.79) 1.89 (.920, 3.87) 1.15 (0.80, 1.65)
aHazard ratio of PCa recurrence per 10-unit increase in risk score
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Fig. 1 Estimated survival probability stratified by obesity status and risk groups (Kattan Score). a Obese patients. b Overweight patients. c Normal
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Fig. 2 Receiver operating characteristics (ROC) curves for the accuracy of each risk score in predicting prostate cancer recurrence
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obese groups. These were not statistically significant dif-
ferences. (Table 4 and Fig. 2).
Discussion
This study is one of the first to examine how patient BMI
may modify the accuracy of commonly used prediction
tools for PCa recurrence. As expected, we observed an in-
crease in the risk of PCa recurrence with an increase in
the risk level of the prediction scores. We observed no sta-
tistically significant associations between risk score cat-
egories and the risk of PCa recurrence across BMI groups.
However, we did observe a larger nonsignificant effect size
among normal weight men (vs. obese) for PCa recurrence
in high risk compared to low risk groups.
The obesity effect on PCa progression is controversial
and has at times seemed conflicting. A recent large cohort
study demonstrated that obesity was associated with a de-
creased risk of low grade PCa but an increased risk of high
grade PCa [6]. Earlier analyses of the SCORE sample indi-
cated that obesity (not stratified by PCa risk group) was
significantly associated with advanced tumor stage and
risk for biochemical recurrence among African American
men, in particular [4]. A recent study of SCORE patients
showed that obesity was associated with a significantly
higher rate of pathologic upgrading of tumors, particularly
among low and medium risk men [11]. Freedland et al.
(2004) showed that moderately and severely obese men
had a greater risk of biochemical failure than normal
weight, overweight, or mildly obese men. After controlling
for preoperative clinical factors and Gleason score, BMI
remained a significant predictor. Moderately and severely
obese men had a 4-fold increased risk of failure [23].
Efstathiou et al. (2007) showed that overweight and obese
patients were almost twice as likely to die of prostate can-
cer as those with normal weight [24].
PCa risk prediction
Widespread use of the PSA test has led to increased de-
tection and treatment of clinically insignificant tumors.
Historically, PCa treatments have been associated with
risk of urinary and sexual dysfunction [25]. Therefore,
high risk patients should be diagnosed as accurately as
possible, since risk status influences patient treatment
options and quality of life (both physical and psycho-
logical.) Even among low risk patients (eligible for active
surveillance protocols), there is the potential for upgrad-
ing and upstaging to pathologically unfavorable disease
[11, 25, 26].
Accurate estimates are essential for physicians to make
recommendations for effective PCa management. No-
mograms are the most appropriate estimates of progno-
sis because they maximize the incorporation of available,
routinely collected, standardized prognostic information
[27]. Although no nomogram predicts with 100% accuracy,
they are the most accurate predictions of cancer outcomes
that we have to date [13]. The accuracy of a nomogram
may vary among patient populations, perhaps predicting
outcomes better depending on risk group or patient charac-
teristics [13]. Direct comparisons of predictive tools are
needed to determine which nomograms are best suited for
particular patient groups. The incorporation of novel bio-
markers for PCa progression may increase predictive accur-
acy for some patients, particularly those at high risk for
PCa recurrence [13, 14]. This increase in accuracy with bio-
markers may not be observed among low risk patients [14].
However, the inclusion of BMI may have greatest utility
among low and medium risk patients [11].
Study limitations and strengths
One of our study limitations is that we use BMI to de-
termine obesity. Other important measures of obesity,
such as waist-to-hip ratio and percent lean body fat were
unavailable for this secondary data analysis. However,
BMI is one of the most clinically relevant measures of
adiposity that we commonly use. Unlike other measures,
BMI is readily available in the medical record and easily
computed upon physical exam. BMI also predicts pros-
tate cancer outcomes [4, 5, 28–30] and is associated with
health outcomes in a trajectory similar to other mea-
sures of adiposity [31, 32].
Biochemical recurrence is not a perfect surrogate for
poor PCa outcomes/fatality. However, biochemical re-
currence is still clinically relevant as a decision point for
adjuvant therapy among patients considered to be at in-
creased risk for poor outcomes because of rising PSA
after primary treatment.
Our study is limited by a small sample of high risk
patients, so evidence is insufficient that our findings are
generalizable to all radical prostatectomy patients. In-
terpretation of our results is also limited by the number
of patients with missing data. There are differences re-
ported between groups with missing data and those
with complete data. This study is a cohort study based
on secondary data analysis. Although more complete
data collection would have been optimal, we were lim-
ited by the data available to us and overcame that limi-
tation with state-of-the-science imputation methods.
We used imputation methods to avoid the problem of
having a very biased sample population which would be
Table 4 Area under the Curve (95% Confidence Interval) by
Obesity Category for Each Risk Score
BMI Group Kattan CaPSURE
Normal weight 0.81 (0.72, 0.89) 0.76 (0.68, 0.84)
Overweight 0.73 (0.68, 0.78) 0.74 (0.69, 0.79)
Obese 0.75 (0.69, 0.81) 0.71 (0.64, 0.78)
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caused by including only patients with complete data.
The original study also was not designed as a
case-control study to investigate BMI associations.
Rather, our patients were stratified by BMI at diagnosis,
so our results reflect actual frequencies of overweight
and obesity in a prostate cancer patient population. We
believe that despite the limitations in study design, the
manuscript still makes an important and novel contri-
bution to the literature. Although we have a limited
number of patients in our analyses, these results pro-
vide evidence that warrants building larger studies that
examine the interplay between prognostic risk group,
obesity, and PCa outcomes. We also have not been able
to adjust our models for additional treatments after
radical prostatectomy or other cause of death during
the follow-up period. The availability of these data in
the medical records was missing for many patients, per-
haps because some patients were seen at other health
systems for treatment during the follow-up period.
Additionally, our study likely was underpowered to
detect interactions between obesity and risk groups. In
a post-hoc power analysis using the observed risk
groupings, we determined that, with good power, large
effects comparing risk groups within an obesity cat-
egory are detectable.
Other commonly used predictive tools, such as CAPRA-S
score, were not studied in this project [33]. Future studies
may include comparisons of nomograms to determine which
has the best predictive ability for diverse PCa patients.
Given the high prevalence of obesity and PCa, the
effect of obesity on PCa outcomes is a relevant clin-
ical issue in men’s health. Our results suggest that the
relationship between risk group and the time to PCa
recurrence does not vary significantly by BMI group.
This implies that patients with extremely severe can-
cer will expect poor outcomes, regardless of their
obesity status. In cases of less severe cancer prognosis
(lower PCa risk group), obese patients may be only
slightly more likely to experience cancer recurrence.
New studies are needed to determine if obesity modi-
fies the utility of various prognostic tools. Clarifying
the role of obesity in the interpretation and accuracy
of PCa prediction tools will impact the selection of
patients for PCa screening, treatment, and prevention
of poor outcomes [34, 35].
Conclusions
Determining which low risk patients are at risk for prostate
cancer recurrence is important for clinical decision making,
especially because the majority of PCa patients are diag-
nosed with localized disease and are likely to be in low risk
prognostic groups [36]. Data are limited regarding the
impact of predictive tools on medical decision making.
Decision making may be facilitated when patients can see
tailored predictions of their outcomes under various condi-
tions [13]. Ultimately, PCa management can be improved
for “low risk” obese patients who often present with unique
disease features and may require a more aggressive treat-
ment approach. Although we used imputation methods to
enlarge the sample with complete data, our study results
suggest that high risk status based on PCa nomogram
scores may be most predictive among normal weight pa-
tients. Additional research in this area is needed.
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